4 September 2015 - CADTH has received notice of a pending submission from Eli Lilly for Basaglar (insulin glargine) for use by patients with type 1 & type 2 diabetes mellitus. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/basaglar

MAESTrO Insight: the PBAC recommended the listing of Basaglar on the PBS in March 2015.